Madison, WI – According to filings with the U.S. Securities and Exchange Commission, Vascugen is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Carter Cliff played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vascugen

Vascular diseases afflict hundreds of millions of people worldwide. Many patients do not respond to standard treatments. We are developing regenerative medicines to address these unmet needs. Regenerative medicine may offer a new opportunity for patients with untreatable degenerative conditions. Vascugen is focused on advancing cell therapies intended to restore function in tissues where there is a loss of blood flow.

To learn more about Vascugen, visit http://vascugen.com/

Contact:
Carter Cliff, Chief Executive Officer
608-514-5564
https://www.linkedin.com/in/cartercliff/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved